Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

CGEM

Cullinan Therapeutics Inc

Oct 14 • 10:06AM ET

16.15

Dollar change -0.07
Percentage change -0.43	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD INCY JAZZ NVAX KURA EXEL BPMC KPTI ESPR ONCY

| Held by: VTI IWM XBI VXF IWO IBB SCHA VTWO VHT DFAC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.10	Insider Own	32.74%	Shs Outstand	42.90M	Perf Week	0.69%
Market Cap	936.38M	Forward P/E	-	EPS next Y	-3.27	Insider Trans	-0.42%	Shs Float	39.00M	Perf Month	-10.03%
Income	-142.16M	PEG	-	EPS next Q	-0.81	Inst Own	77.50%	Short Float	23.61%	Perf Quarter	-15.36%
Sales	0.00M	P/S	-	EPS this Y	11.76%	Inst Trans	133.71%	Short Ratio	14.39	Perf Half Y	-2.42%
Book/sh	11.34	P/B	1.42	EPS next Y	-0.34%	ROA	-23.63%	Short Interest	9.21M	Perf Year	85.21%
Cash/sh	11.43	P/C	1.41	EPS next 5Y	-	ROE	-24.60%	52W Range	7.64 - 30.19	Perf YTD	58.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-62.42%	ROI	-21.61%	52W High	-46.50%	Beta	-0.13
Dividend TTM	-	Quick Ratio	28.87	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	111.39%	ATR (14)	0.85
Dividend Ex-Date	-	Current Ratio	28.87	EPS Y/Y TTM	7.74%	Oper. Margin	0.00%	RSI (14)	43.94	Volatility	3.88% 5.96%
Employees	85	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	32.71
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	5.32%	Payout	-	Rel Volume	0.23	Prev Close	16.22
Sales Surprise	-	EPS Surprise	-3.43%	Sales Q/Q	-	Earnings	Aug 08 BMO	Avg Volume	639.82K	Price	16.15
SMA20	-3.28%	SMA50	-6.55%	SMA200	-10.31%	Trades		Volume	20,051	Change	-0.43%

Date	Action	Analyst	Rating Change	Price Target Change
May-01-24	Initiated	Stifel	Buy	$40
Apr-15-24	Initiated	William Blair	Outperform
Feb-15-24	Initiated	Wedbush	Outperform	$30
Jun-15-23	Initiated	TD Cowen	Outperform
Nov-21-22	Initiated	BTIG Research	Buy	$20
Apr-27-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$40
Feb-02-21	Initiated	SVB Leerink	Outperform	$52
Feb-02-21	Initiated	Morgan Stanley	Equal-Weight	$38
Feb-02-21	Initiated	Evercore ISI	Outperform	$55
Feb-01-21	Initiated	H.C. Wainwright	Buy	$47

Sep-17-24 07:00AM	Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Sep-16-24 07:00AM	Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus (GlobeNewswire) -5.68%
Sep-14-24 04:15AM	Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024 (GlobeNewswire)
Aug-28-24 08:00AM	Cullinan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
06:26AM	Loading…
Jun-03-24 06:26AM	Cullinan Therapeutics announces success for zipalertinib as combo therapy (Clinical Trials Arena)
Jun-01-24 07:00AM	Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib (GlobeNewswire)
May-24-24 08:00AM	Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire) +6.53%
May-23-24 05:04PM	Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 (GlobeNewswire)
May-16-24 12:03PM	HC Wainwright Adjusts Price Target on Cullinan Oncology to $28 From $29, Maintains Buy Rating (MT Newswires) -10.89%
May-15-24 10:54PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 03:09AM	Insider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ... (GuruFocus.com)
May-01-24 07:05AM	Stifel Initiates Cullinan Oncology With Buy Rating, $40 Price Target (MT Newswires)
Apr-29-24 07:00AM	Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer (GlobeNewswire) +7.19%
04:29PM	Loading…
Apr-24-24 04:29PM	Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday? (Benzinga) +13.32%
10:09AM	Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024 (GlobeNewswire)
Apr-16-24 03:32PM	Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity (Benzinga)
07:00AM	Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases (GlobeNewswire)
06:59AM	Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement (GlobeNewswire)
04:48AM	Cullinan changes name, pivots to autoimmune disease (BioPharma Dive)
Mar-16-24 05:31AM	Cullinan Oncology Inc (CGEM) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com)
Mar-14-24 12:53PM	CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-01-24 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Feb-27-24 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-24 09:21AM	13 Best Booming Stocks to Buy Right Now (Insider Monkey)
Feb-02-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-30-24 11:01PM	Chief Business Officer Corrine Savill Sells 40,000 Shares of Cullinan Oncology Inc (GuruFocus.com)
Jan-24-24 07:02PM	Insider Sell: Cullinan Oncology Inc's Chief Business Officer Corrine Savill Sold 40,000 Shares (GuruFocus.com)
04:53PM	Loading…
Dec-18-23 04:53PM	Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.80%
Dec-14-23 04:30PM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines (GlobeNewswire)
Nov-08-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 12:01PM	Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 (GlobeNewswire) +5.53%
Oct-30-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 07:00AM	Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (GlobeNewswire)
Aug-03-23 04:15PM	REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations (PR Newswire)
Jul-31-23 08:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jun-09-23 04:07PM	Why Shares of Cullinan Oncology Jumped This Week (Motley Fool)
May-25-23 05:00PM	Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 (GlobeNewswire) +5.13%
May-11-23 04:01PM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-26-23 10:08AM	Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 (GlobeNewswire)
Apr-20-23 07:00AM	Cullinan Oncology to Participate in Stifels 2023 Targeted Oncology Days (GlobeNewswire)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey)
Mar-27-23 07:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines (GlobeNewswire)
Mar-14-23 04:35PM	Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Feb-27-23 08:00AM	Cullinan Oncology to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-13-23 07:00PM	Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed (GlobeNewswire)
Feb-02-23 04:01PM	Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-01-23 04:42PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-24-23 08:00AM	Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +5.53%
Jan-23-23 11:07AM	12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds (Insider Monkey)
Jan-03-23 05:13PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-28-22 10:31PM	11 Cheap Value Stocks to Buy According to Seth Klarman (Insider Monkey)
Dec-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-14-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-02-22 08:00AM	Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors (GlobeNewswire)
Nov-01-22 05:23PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Cullinan Oncology to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-25-22 07:00AM	Cullinan Oncology Significantly Increases Ownership Stake in its MICA Subsidiary which Holds Worldwide Rights to Clinical-Stage Novel Monoclonal Antibody CLN-619 (GlobeNewswire) +6.03%
Oct-03-22 04:50PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-22 08:00AM	Cullinan Oncology to Participate in the HC Wainwright Global Investment Conference and the Morgan Stanley Healthcare Conference (GlobeNewswire) +5.36%
Sep-01-22 05:27PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 04:57PM	Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer (GlobeNewswire)
Aug-10-22 07:00AM	Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-01-22 04:55PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.24%
08:00AM	Cullinan Oncology to Participate in BTIG Biotechnology Conference and Canaccord Growth Conference (GlobeNewswire)
Jul-29-22 05:00AM	Why are Massachusetts CEOs paid so much money? Here's a primer (American City Business Journals)
05:00AM	Best bang for the buck: Which CEOs are a bargain for shareholders? (American City Business Journals)
Jul-05-22 04:01PM	Cullinan Oncology to Participate in William Blair Biotech Focus Conference (GlobeNewswire)
Jul-01-22 04:37PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-23-22 08:00AM	Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 (GlobeNewswire)
Jun-01-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.08%
May-31-22 08:00AM	Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire) -6.88%
May-26-22 08:45AM	Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting (GlobeNewswire)
May-19-22 08:00AM	Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference (GlobeNewswire) -5.01%
May-16-22 06:45AM	Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-12-22 11:18AM	Why Are Cullinan Oncology Shares Rising Today? (Benzinga) +23.12%
02:00AM	Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taihos Acquisition of Cullinan Pearl (GlobeNewswire)
May-08-22 09:23AM	Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth (Simply Wall St.)
May-02-22 05:00PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.34%
Apr-27-22 10:00AM	Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting (GlobeNewswire)
Apr-05-22 08:00AM	Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Apr-04-22 04:34PM	Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.55%
Mar-29-22 07:54AM	Cullinan Oncology Lead Cancer Program Shows Confirmed ORR Of 41% In Lung Cancer Setting (Benzinga)
Mar-28-22 04:01PM	Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients (GlobeNewswire)
Mar-17-22 07:08AM	Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
07:00AM	Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022 (GlobeNewswire)
Mar-09-22 08:00AM	Cullinan Oncology to Present at the Barclays Global Healthcare Conference (GlobeNewswire) +8.91%
Mar-08-22 05:30PM	Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022 (GlobeNewswire)
Feb-28-22 08:00AM	Cullinan Oncology Expands Leadership Team and Board of Directors with Appointments of Jeffrey Jones, M.D., MPH, MBA to Chief Medical Officer and Anne-Marie Martin Ph.D. to Board of Directors (GlobeNewswire)
Feb-12-22 06:50AM	Investors in Cullinan Oncology (NASDAQ:CGEM) have unfortunately lost 66% over the last year (Simply Wall St.)
Feb-07-22 06:30AM	Cullinan Oncology to Present at SVB Leerinks 11th Annual Global Healthcare Conference (GlobeNewswire) +6.52%
Jan-10-22 06:30AM	Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment (GlobeNewswire)
Jan-05-22 09:00AM	Cullinan Oncology to Present at Upcoming Virtual Investor Conferences (GlobeNewswire) -6.69%
Jan-04-22 07:34AM	Cullinan Oncology stock shoots higher after lung cancer treatment granted BTD by FDA (MarketWatch)
07:00AM	FDA Grants Breakthrough Therapy Designation for Cullinan Oncologys CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer (GlobeNewswire)

Cullinan Therapeutics, Inc. is a biopharmaceutical company engaged in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Michaelson Jennifer	Chief Scientific Officer	Sep 05 '24	Sale	18.09	8,000	144,720	115,942	Sep 09 05:30 PM
JENNIFER MICHAELSON & MARC D M	Officer	Sep 05 '24	Proposed Sale	18.68	16,000	298,880		Sep 05 04:27 PM
Michaelson Jennifer	Chief Scientific Officer	Jul 05 '24	Sale	16.33	8,000	130,640	123,942	Jul 09 05:30 PM
Ebeling Thomas	Director	Jun 10 '24	Option Exercise	13.00	18,450	239,850	186,653	Jun 11 06:00 PM
Michaelson Jennifer	Chief Scientific Officer	May 06 '24	Option Exercise	4.30	50,000	215,000	187,582	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 07 '24	Option Exercise	4.30	5,606	24,106	135,188	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 06 '24	Sale	28.07	58,000	1,628,159	129,582	May 08 07:30 PM
Michaelson Jennifer	Chief Scientific Officer	May 07 '24	Sale	30.06	5,606	168,516	129,582	May 08 07:30 PM
Savill Corrine	Chief Business Officer	Feb 01 '24	Option Exercise	4.30	40,000	172,000	205,990	Feb 02 09:35 PM
Savill Corrine	Chief Business Officer	Feb 01 '24	Sale	16.18	40,000	647,200	165,990	Feb 02 09:35 PM
Savill Corrine	Chief Business Officer	Jan 29 '24	Option Exercise	4.30	40,000	172,000	205,990	Jan 30 07:00 PM
Savill Corrine	Chief Business Officer	Jan 29 '24	Sale	14.09	40,000	563,600	165,990	Jan 30 07:00 PM
Savill Corrine	Chief Business Officer	Jan 23 '24	Option Exercise	4.30	21,316	91,659	187,306	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 22 '24	Option Exercise	4.30	14,559	62,604	184,674	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 23 '24	Sale	12.46	21,316	265,597	165,990	Jan 24 05:00 PM
Savill Corrine	Chief Business Officer	Jan 22 '24	Sale	12.14	18,684	226,911	165,990	Jan 24 05:00 PM
AHMED NADIM	President and CEO	Dec 26 '23	Sale	9.24	4,272	39,473	111,550	Dec 27 06:30 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 21 '23	Sale	8.50	1,860	15,810	56,191	Dec 22 05:30 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 21 '23	Sale	8.50	1,400	11,900	44,133	Dec 22 05:30 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 21 '23	Sale	8.50	1,920	16,320	83,919	Dec 22 05:30 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 21 '23	Sale	8.50	1,145	9,732	87,582	Dec 22 05:30 PM
Jones Jeffrey Alan	Chief Medical Officer	Dec 18 '23	Sale	8.22	386	3,173	58,051	Dec 20 06:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 18 '23	Sale	8.22	238	1,956	88,727	Dec 20 06:00 PM
SUMER JACQUELYN L	Chief Legal Officer	Dec 18 '23	Sale	8.22	290	2,384	45,533	Dec 20 06:00 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 18 '23	Sale	8.22	398	3,272	85,839	Dec 20 06:00 PM
Trigilio Jeffrey	Chief Financial Officer	Dec 12 '23	Sale	7.81	1,926	15,042	86,237	Dec 13 08:00 PM
Michaelson Jennifer	Chief Scientific Officer	Dec 12 '23	Sale	7.81	1,068	8,341	88,965	Dec 13 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CGEM

Cullinan Therapeutics Inc

Upgrade your FINVIZ experience